TEVATeva Pharmaceutical Industries Limited

$36B

Q2 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$5.7B+12.9% YoY

Gross Profit

$2.8B49.6% margin

Operating Income

-$5.7B-100.9% margin

Net Income

-$6.0B-105.0% margin

EPS (Diluted)

$-5.87

QoQ Revenue Growth

+1.0%

Cash Flow

Operating Cash Flow

$741M

Free Cash Flow

$548M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$86.4B

Total Liabilities

$56.7B

Stockholders' Equity

$28.0B

Cash & Equivalents

$599M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.7B	$5.0B	+12.9%
Gross Profit	$2.8B	$2.9B	-1.9%
Operating Income	-$5.7B	$361M	-1690.0%
Net Income	-$6.0B	$254M	-2450.4%

TEVA Q2 2017 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena